Cargando…

Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis

PURPOSE: The purpose of this study was to evaluate the efficacy and safety of induction chemotherapy with docetaxel, capecitabine, and cisplatin (DXP) plus bevacizumab (BEV) on initially unresectable locally advanced gastric cancer (LAGC) or paraaortic lymph node (PAN) metastatic gastric cancer (GC)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jwa Hoon, Park, Sook Ryun, Ryu, Min-Hee, Ryoo, Baek-Yeol, Kim, Kyu-pyo, Kim, Beom Su, Yoo, Moon-Won, Yook, Jeong Hwan, Kim, Byung Sik, Kim, Jihun, Byeon, Sun-Ju, Kang, Yoon-Koo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912143/ https://www.ncbi.nlm.nih.gov/pubmed/28546521 http://dx.doi.org/10.4143/crt.2017.005

Ejemplares similares

A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
por: Lee, Keun-Wook, et al.
Publicado: (2017)

Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis
por: Yoo, Changhoon, et al.
Publicado: (2016)

Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study
por: Yu, Deguo, et al.
Publicado: (2022)

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer
por: Lee, S-H, et al.
Publicado: (2004)

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer
por: Park, Y H, et al.
Publicado: (2004)

Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
por: Devata, Sumana, et al.
Publicado: (2012)

A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer
por: Brenner, Baruch, et al.
Publicado: (2016)

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer
por: Chadha, Awalpreet S., et al.
Publicado: (2016)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Phase II study of docetaxel, cisplatin and capecitabine as preoperative chemotherapy in resectable gastric cancer
por: Dassen, Anneriet E, et al.
Publicado: (2016)

Complete Remission of Advanced Gastric Cancer in Response to Chemotherapy With Docetaxel, Cisplatin and Capecitabine (dcx)
por: Marroqui, Asuncion Juarez, et al.
Publicado: (2011)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial
por: Chen, Ming-Huang, et al.
Publicado: (2016)

Optimal Extent of Prophylactic Irradiation of Paraaortic Lymph Nodes in Patients with Uterine Cervical Cancer
por: Choi, Jinhyun, et al.
Publicado: (2015)

Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen
por: Yoo, Changhoon, et al.
Publicado: (2017)

Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study
por: Maeda, Osamu, et al.
Publicado: (2017)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)
por: Ryu, Min‐Hee, et al.
Publicado: (2022)

Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study
por: Jeong, H., et al.
Publicado: (2021)

A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
por: Yoo, Changhoon, et al.
Publicado: (2015)

Thoracoscopic resection of a paraaortic bronchogenic cyst
por: Mondello, Baldassare, et al.
Publicado: (2010)

Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma
por: Park, Se Hoon, et al.
Publicado: (2006)

Pathological complete response to mFOLFOX6 plus cetuximab therapy for unresectable colon cancer with multiple paraaortic lymph node metastases
por: Suetsugu, Tomonari, et al.
Publicado: (2018)

Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer
por: Takayama, T, et al.
Publicado: (2007)

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
por: Kim, Beom Kyung, et al.
Publicado: (2022)

Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy
por: Kang, H J, et al.
Publicado: (2005)

New Peritoneal Traction Device for Laparoscopic Paraaortic Lymphadenectomy
por: Mabuchi, Seiji, et al.
Publicado: (2020)

Paraaortic Lymphadenectomy in Gynecologic Oncology—Significance of Vessels Variations
por: Kostov, Stoyan, et al.
Publicado: (2022)

Definitive Chemoradiotherapy with Capecitabine and Cisplatin in Patients with Esophageal Cancer: A Pilot Study
por: Lee, Soo Jung, et al.
Publicado: (2009)

Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer
por: Oh, S C, et al.
Publicado: (2005)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
por: Martin, L P, et al.
Publicado: (2012)

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin
por: Hyung, Jaewon, et al.
Publicado: (2019)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study
por: Jackson, Christopher GCA, et al.
Publicado: (2014)

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
por: Kim, Miso, et al.
Publicado: (2017)

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
por: Lee, J-L, et al.
Publicado: (2008)

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
por: Yang, Hannah, et al.
Publicado: (2023)

Increased incidence of chemoport-related thrombosis in patients with colorectal cancer receiving bevacizumab: A single-institutional experience
por: Kim, Jwa Hoon, et al.
Publicado: (2018)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients
por: Kim, Bum Jun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_aiia10nairibd1niord0fslhu8